Ratings by Leerink Partners (Mani Foroohar)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/6/2026 | Regenxbio Inc. | RGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2026 | Scholar Rock | SRRK | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2026 | Mirum Pharmaceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 1/30/2026 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 1/8/2026 | Sarepta Therapeutics | SRPT | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/15/2025 | Regenxbio Inc. | RGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/12/2025 | Tenaya Therapeutics Inc | TNYA | Maintain | Outperform (N/A) |
|
Details | ||
| 12/10/2025 | Mirum Pharmaceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2025 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 11/13/2025 | Caribou Biosciences Inc. | CRBU | Maintain | Outperform (N/A) |
|
Details | ||
| 11/12/2025 | Engene Holdings Inc. | ENGN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/31/2025 | 4D Molecular Therapeutics | FDMT | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2025 | Ionis Pharmaceuticals | IONS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2025 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2025 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 10/23/2025 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 10/6/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/3/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/24/2025 | Scholar Rock | SRRK | Maintain | Outperform (N/A) |
|
Details | ||
| 9/24/2025 | Ionis Pharmaceuticals | IONS | Maintain | Outperform (N/A) |
|
Details | ||
| 9/15/2025 | Scholar Rock | SRRK | New Coverage | Outperform (N/A) |
31.67 (45.29) |
43.01% | Details | |
| 9/10/2025 | CAMP4 Therapeutics Corp | CAMP | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2025 | Lexeo Therapeutics | LXEO | Maintain | Outperform (N/A) |
|
Details | ||
| 8/11/2025 | 4D Molecular Therapeutics | FDMT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2025 | Arrowhead Pharma | ARWR | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/8/2025 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2025 | Ionis Pharmaceuticals | IONS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2025 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/4/2025 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 7/18/2025 | Sarepta Therapeutics | SRPT | Downgrade | Market Perform (Outperform) |
21.97 (16.71) |
-23.94% | Details | |
| 7/18/2025 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 6/5/2025 | Regenxbio Inc. | RGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/27/2025 | Rocket Pharmaceuticals | RCKT | Downgrade | Market Perform (Outperform) |
6.27 (4.41) |
-29.67% | Details | |
| 5/27/2025 | Lexeo Therapeutics | LXEO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/24/2025 | Lexeo Therapeutics | LXEO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/21/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/18/2025 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/4/2025 | Tenaya Therapeutics Inc | TNYA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/13/2025 | 4D Molecular Therapeutics | FDMT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/3/2024 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 11/5/2024 | CAMP4 Therapeutics Corp | CAMP | New Coverage | Outperform (N/A) |
8.22 (4.20) |
-48.91% | Details | |
| 10/18/2024 | Tenaya Therapeutics Inc | TNYA | Maintain | Outperform (N/A) |
|
Details | ||
| 10/14/2024 | Benitec BioPharma | BNTC | Maintain | Outperform (N/A) |
|
Details | ||
| 10/4/2024 | Editas Medicine | EDIT | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/27/2024 | Benitec BioPharma | BNTC | Maintain | Outperform (N/A) |
|
Details | ||
| 9/27/2024 | Engene Holdings Inc. | ENGN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/3/2024 | Recursion Pharmaceuticals | RXRX | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/12/2024 | Lexeo Therapeutics | LXEO | Maintain | Outperform (N/A) |
|
Details | ||
| 7/24/2024 | Ionis Pharmaceuticals | IONS | Upgrade | Outperform (Market Perform) |
50.43 (74.04) |
46.82% | Details | |
| 7/22/2024 | Benitec BioPharma | BNTC | New Coverage | Outperform (N/A) |
9.22 (11.34) |
22.99% | Details | |
| 7/2/2024 | Schrodinger | SDGR | New Coverage | Outperform (N/A) |
18.76 (12.74) |
-32.09% | Details | |
| 6/24/2024 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 6/18/2024 | Mirum Pharamceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2024 | Arrowhead Pharma | ARWR | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/29/2024 | Neurogene | NGNE | New Coverage | Outperform (N/A) |
29.96 (22.17) |
-26% | Details | |
| 4/25/2024 | CureVac | CVAC | Downgrade | Market Perform (Outperform) |
2.51 (4.66) |
85.66% | Details | |
| 3/13/2024 | Mirum Pharamceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2024 | Regenxbio Inc. | RGNX | Upgrade | Outperform (Market Perform) |
24.61 (8.65) |
-64.85% | Details | |
| 2/20/2024 | Engene Holdings Inc. | ENGN | New Coverage | Outperform (N/A) |
16.15 (8.68) |
-46.25% | Details | |
| 1/22/2024 | Ionis Pharmaceuticals | IONS | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/22/2023 | Allovir Inc. | ALVR | Downgrade | Market Perform (Outperform) |
2.33 (9.81) |
321.03% | Details | |
| 11/30/2023 | Tenaya Therapeutics Inc | TNYA | New Coverage | Outperform (N/A) |
1.86 (0.89) |
-52.15% | Details | |
| 11/28/2023 | Lexeo Therapeutics | LXEO | New Coverage | Outperform (N/A) |
11.00 (6.85) |
-37.73% | Details | |
| 10/18/2023 | 4D Molecular Therapeutics | FDMT | Upgrade | Outperform (Market Perform) |
9.76 (8.48) |
-13.11% | Details | |
| 8/7/2023 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 7/17/2023 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 6/8/2023 | CureVac | CVAC | New Coverage | Outperform (N/A) |
9.92 (4.66) |
-53.02% | Details | |
| 5/12/2023 | Arrowhead Pharma | ARWR | Downgrade | Market Perform (Outperform) |
40.08 (59.82) |
49.25% | Details | |
| 4/26/2023 | Allovir Inc. | ALVR | Maintain | Outperform (N/A) |
|
Details | ||
| 4/12/2023 | Arrowhead Pharma | ARWR | Upgrade | Outperform (Market Perform) |
26.23 (59.82) |
128.06% | Details | |
| 3/15/2023 | Decibel Therapeutics Inc | DBTX | Downgrade | Market Perform (Outperform) |
4.08 (4.91) |
20.34% | Details | |
| 3/6/2023 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/24/2023 | Moderna | MRNA | Downgrade | Underperform (Market Perform) |
147.57 (52.52) |
-64.41% | Details | |
| 1/6/2023 | Graphite Bio Inc | GRPH | Downgrade | Market Perform (Outperform) |
3.06 (3.18) |
3.92% | Details | |
| 12/22/2022 | Rocket Pharmaceuticals | RCKT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/1/2022 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/30/2022 | Regenxbio Inc. | RGNX | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/30/2022 | Ionis Pharmaceuticals | IONS | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/17/2022 | Editas Medicine | EDIT | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/14/2022 | 4D Molecular Therapeutics | FDMT | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/9/2022 | Arrowhead Pharma | ARWR | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/21/2022 | Moderna | MRNA | Upgrade | Market Perform (Underperform) |
118.38 (52.52) |
-55.63% | Details | |
| 10/20/2022 | Talaris Therapeutics | TALS | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/17/2022 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 9/19/2022 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2022 | 4D Molecular Therapeutics | FDMT | Downgrade | Market Perform (Outperform) |
10.40 (8.48) |
-18.46% | Details | |
| 7/1/2022 | Talaris Therapeutics | TALS | Downgrade | Market Perform (Outperform) |
7.13 (2.72) |
-61.85% | Details | |
| 6/21/2022 | Ionis Pharmaceuticals | IONS | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/14/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/20/2022 | Rocket Pharmaceuticals | RCKT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2022 | Caribou Biosciences Inc. | CRBU | Maintain | Outperform (N/A) |
|
Details | ||
| 4/27/2022 | Mirum Pharamceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/8/2022 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/4/2022 | Recursion Pharmaceuticals | RXRX | Downgrade | Market Perform (Outperform) |
9.70 (3.46) |
-64.33% | Details | |
| 2/1/2022 | Sio Gene Therapies | SIOX | Downgrade | Market Perform (Outperform) |
1.17 (0.42) |
-64.1% | Details | |
| 1/4/2022 | 4D Molecular Therapeutics | FDMT | New Coverage | Outperform (N/A) |
22.17 (8.48) |
-61.75% | Details | |
| 12/27/2021 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/16/2021 | Ionis Pharmaceuticals | IONS | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/30/2021 | Abeona Therapeutics | ABEO | Downgrade | Market Perform (Outperform) |
0.65 (4.85) |
646.15% | Details | |
| 11/5/2021 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 9/13/2021 | Regenxbio Inc. | RGNX | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/13/2021 | Mirum Pharamceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 8/19/2021 | Amryt | AMYT | New Coverage | Outperform (N/A) |
11.90 (14.70) |
23.53% | Details | |
| 8/17/2021 | Caribou Biosciences Inc. | CRBU | New Coverage | Outperform (N/A) |
26.48 (1.82) |
-93.13% | Details | |
| 8/10/2021 | Decibel Therapeutics Inc | DBTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2021 | Dicerna Pharmaceuticals | DRNA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2021 | bluebird bio | BLUE | Downgrade | Market Perform (Outperform) |
25.03 (4.97) |
-80.14% | Details | |
| 6/28/2021 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/20/2021 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2021 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 5/3/2021 | Adverum Biotechnologies | ADVM | Downgrade | Market Perform (Outperform) |
3.90 (4.36) |
11.79% | Details | |
| 4/1/2021 | Rocket Pharmaceuticals | RCKT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/29/2021 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2021 | Decibel Therapeutics Inc | DBTX | New Coverage | Outperform (N/A) |
13.26 (4.91) |
-62.97% | Details | |
| 2/16/2021 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/21/2020 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2020 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2020 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2020 | Regenxbio Inc. | RGNX | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/5/2020 | Eidos Therapeutics | EIDX | Downgrade | Market Perform (Outperform) |
51.92 (122.21) |
135.38% | Details | |
| 8/7/2020 | Regenxbio Inc. | RGNX | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/7/2020 | Alnylam Pharmaceuticals | ALNY | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/12/2020 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
| 5/11/2020 | Eidos Therapeutics | EIDX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/21/2020 | Regenxbio Inc. | RGNX | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/7/2020 | Dicerna Pharmaceuticals | DRNA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2020 | Abeona Therapeutics | ABEO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/16/2020 | Avrobio Inc. | AVRO | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/10/2020 | Abeona Therapeutics | ABEO | New Coverage | Outperform (N/A) |
2.51 (4.85) |
93.23% | Details | |
| 2/6/2020 | Arrowhead Research | ARWR | Maintain | Underperform (N/A) |
|
Details | ||
| 1/23/2020 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 1/3/2020 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/31/2019 | WAVE Life Sciences | WVE | Downgrade | Market Perform (Outperform) |
7.99 (13.12) |
64.21% | Details | |
| 12/18/2019 | Regenxbio Inc. | RGNX | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/26/2019 | bluebird bio | BLUE | Upgrade | Outperform (Market Perform) |
74.84 (25.03) |
-66.56% | Details | |
| 11/1/2019 | Dicerna Pharmaceuticals | DRNA | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2019 | Eidos Therapeutics | EIDX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2019 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 8/22/2019 | Regenxbio Inc. | RGNX | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/20/2019 | Regenxbio Inc. | RGNX | Upgrade | Market Perform (Underperform) |
37.54 (8.65) |
-76.96% | Details | |
| 8/20/2019 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/20/2019 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/20/2019 | Eidos Therapeutics | EIDX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/20/2019 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/6/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/23/2019 | Ionis Pharmaceuticals | IONS | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/21/2019 | Axovant Gene Therapies Ltd. | AXGT | New Coverage | Outperform (N/A) |
5.58 (2.10) |
-62.37% | Details | |
| 6/18/2019 | bluebird bio | BLUE | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/7/2019 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/9/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/15/2019 | Ionis Pharmaceuticals | IONS | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/7/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/5/2019 | bluebird bio | BLUE | Downgrade | Market Perform (Outperform) |
156.66 (74.84) |
-52.23% | Details | |
| 3/3/2019 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 1/25/2019 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 1/25/2019 | Dicerna Pharmaceuticals | DRNA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/25/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/28/2018 | Regenxbio Inc. | RGNX | New Coverage | Underperform (N/A) |
64.99 (37.54) |
-42.24% | Details | |
| 11/28/2018 | Alnylam Pharmaceuticals | ALNY | New Coverage | Market Perform (N/A) |
78.35 (320.66) |
309.27% | Details | |
| 11/28/2018 | Ionis Pharmaceuticals | IONS | New Coverage | Market Perform (N/A) |
56.26 (74.04) |
31.6% | Details | |
| 11/28/2018 | WAVE Life Sciences | WVE | New Coverage | Outperform (N/A) |
44.04 (7.99) |
-81.86% | Details | |
| 11/28/2018 | Avrobio Inc. | AVRO | New Coverage | Market Perform (N/A) |
26.19 (1.40) |
-94.65% | Details | |
| 11/28/2018 | Intellia Therapeutics | NTLA | New Coverage | Outperform (N/A) |
17.17 (13.44) |
-21.72% | Details | |
| 11/28/2018 | Rocket Pharmaceuticals | RCKT | New Coverage | Outperform (N/A) |
16.16 (6.27) |
-61.2% | Details | |
| 11/28/2018 | Eidos Therapeutics | EIDX | New Coverage | Outperform (N/A) |
14.24 (51.92) |
264.61% | Details | |
| 11/28/2018 | Dicerna Pharmaceuticals | DRNA | New Coverage | Outperform (N/A) |
14.48 (38.22) |
163.95% | Details | |
| 11/28/2018 | bluebird bio | BLUE | New Coverage | Outperform (N/A) |
128.24 (156.66) |
22.16% | Details |
